on INVENTIVA (EPA:IVA)
Inventiva at the 2026 Jefferies Global Healthcare Conference
Biopharmaceutical company Inventiva, listed on Euronext Paris and Nasdaq, announces that its CEO, Andrew Obenshain, will participate in the Jefferies Global Healthcare Conference 2026. The event will take place from June 2nd to 4th in New York. Inventiva's presentation is scheduled for June 3rd at 5:30 p.m. local time. Individual meetings will also be held concurrently.
Inventiva is focused on developing an oral therapy to treat steatohepatitis associated with metabolic dysfunction (MASH). It is currently conducting a phase 3 clinical trial of lanifibranor, a molecule intended for adults suffering from this chronic liver disease.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news